TNYA
Tenaya Therapeutics, Inc.
$0.6860
-5.77%
$154.1M
No data for this timeframe.
Vol
Market Cap$154.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$8.5M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 12S
Insider Net $-$2.8M
Reddit Sentiment45° Neutral
SEC Reports7
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001858848·Prev Close $0.7280
Recent Activity
Jun 9, 2026
short_volume
Short Volume: TNYA — 56.4% short (1.1M / 1.9M)
Short: 1,079,149 | Exempt: 8,152 | TRF Vol: 1,913,399 | Short Ratio: 56.4% | Off-exchange volume (da
May 29, 2026
SEC
Tenaya Therapeutics held its 2026 annual meeting on May 27, 2026, where shareholders approved an amended and restated 20
8-K — Impact 3/10
May 28, 2026
Insider
Burroughs Amy L. sold 120,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
Lee June sold 120,000 shares
Director @ $0.00 ($0.00)
May 28, 2026
Insider
Parschauer Karah Herdman sold 120,000 shares
Director @ $0.00 ($0.00)
May 16, 2026
SEC
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
ANALYST-UPGRADE — Impact 1/10
Apr 16, 2026
SEC
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
ANALYST-UPGRADE — Impact 1/10
Inst.
VANGUARD GROUP INC — ADD
8,560,108 shares ($6.1M)
Price Targets
$4.00
+463.4% upside
Strong Buy
Current $0.7100
Low $2.00
Median $3.50
High $8.00
6 analysts
$2.00
$8.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Dec 18, 2025 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Dec 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 12, 2025 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +39.7% | $-0.14 — $-0.04 | 54% YoY | 7 |
| Next Q | $-0.10 ▲ +16.7% | $-0.14 — $-0.08 | 18% YoY | 7 |
| Current FY | $-0.38 ▲ +10.8% | $-0.59 — $-0.27 | 35% YoY | 8 |
| Next FY | $-0.41 ▲ +8.4% | $-0.59 — $-0.29 | -8% YoY | 5 |
Latest Reports
BULLISH
ANALYST-UPGRADE
1/10
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
May 16, 2026
MIXED
ANALYST-UPGRADE
1/10
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
Apr 16, 2026
MIXED
Press
6/10
Tenaya Therapeutics reported financial results for Q4 and full year 2025, highlighted by reduced net loss and a strength
Mar 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $6.1M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.3M | NEW |
| TWO SIGMA INVESTMENTS, LP | $900.8K | ADD |
| MORGAN STANLEY | $148.3K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $35.6K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Burroughs Amy | A | $0.00 |
| May 28, 2026 | Lee June | A | $0.00 |
| May 28, 2026 | Parschauer Karah | A | $0.00 |
| May 28, 2026 | Srivastava Deepak | A | $0.00 |
| May 28, 2026 | Stehman-Breen Catherine | A | $0.00 |
Reddit Sentiment
45°▼
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $8.5M total value (11,974,320 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,560,108 | $6.1M | 71.5% | ADD +69.0% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,850,867 | $1.3M | 15.4% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,266,075 | $900.8K | 10.6% | ADD +39.0% |
| 4 | MORGAN STANLEY | 208,431 | $148.3K | 1.7% | ADD +44.2% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 50,000 | $35.6K | 0.4% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 32,075 | $22.8K | 0.3% | TRIM -43.6% |
| 7 | WELLS FARGO & COMPANY/MN | 4,000 | $2.8K | 0.0% | DOUBLED +300.0% |
| 8 | FMR LLC | 2,764 | $2.0K | 0.0% | NEAR_EXIT -89.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 5,064,857 | 8,560,108 | +69.0% | $6.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 910,568 | 1,266,075 | +39.0% | $900.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,000 | 4,000 | +300.0% | $2.8K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 474,787 | 910,568 | +91.8% | $1.5M | 2025-Q3 |
| UBS Group AG | ADD | 120,176 | 196,727 | +63.7% | $318.7K | 2025-Q3 |
| MORGAN STANLEY | ADD | 115,879 | 167,089 | +44.2% | $270.7K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 50,000 | — | $81.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 2,090 | 1,000 | -52.2% | $1.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 367,629 | 474,787 | +29.1% | $290.2K | 2025-Q2 |
| UBS Group AG | TRIM | 254,744 | 120,176 | -52.8% | $73.4K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 314,549 | 115,879 | -63.2% | $70.8K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 93,694 | 52,855 | -43.6% | $32.3K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 26,220 | 2,764 | -89.5% | $1.7K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 44,884 | 2,090 | -95.3% | $1.3K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 130,192 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 1,541,725 | — | $878.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 44,771 | 367,629 | +721.1% | $209.6K | 2025-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 1,488,306 | 314,549 | -78.9% | $179.3K | 2025-Q1 |
| UBS Group AG | TRIM | 478,508 | 254,744 | -46.8% | $145.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 601,286 | 152,800 | -74.6% | $87.1K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 31,553 | 44,884 | +42.2% | $25.6K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 312,991 | 1,488,306 | +375.5% | $2.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 2,336,451 | 601,286 | -74.3% | $859.8K | 2024-Q4 |
| UBS Group AG | DOUBLED | 26,138 | 478,508 | +1730.7% | $684.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,315 | 31,553 | +29.8% | $45.1K | 2024-Q4 |
11 unique insiders with 12 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Burroughs Amy L. | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Lee June | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Parschauer Karah Herdman | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Srivastava Deepak | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Stehman-Breen Catherine | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Walsh Jeffrey T. | Director | A | 120,000 | $0.00 | $0.00 |
| May 28, 2026 | Williams R Sanders | Director | A | 120,000 | $0.00 | $0.00 |
| May 18, 2026 | Tingley Whittemore | Chief Medical Officer | SELL | 3,121 | $0.7936 | $2.5K |
| May 18, 2026 | Higa Tomohiro | SVP, Finance | SELL | 1,485 | $0.7932 | $1.2K |
| May 18, 2026 | Ali Faraz | Chief Executive Officer | SELL | 3,390 | $0.7934 | $2.7K |
| Feb 25, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 1,649,281 | $0.5624 | $927.6K |
| Feb 24, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 309,228 | $0.6153 | $190.3K |
| Feb 23, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 143,709 | $0.5972 | $85.8K |
| Feb 20, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 245,965 | $0.6149 | $151.2K |
| Feb 17, 2026 | Higa Tomohiro | SVP, Finance | SELL | 611 | $0.6434 | $393.12 |
| Feb 17, 2026 | Tingley Whittemore | Chief Medical Officer | SELL | 1,642 | $0.6432 | $1.1K |
| Feb 17, 2026 | Ali Faraz | Chief Executive Officer | SELL | 5,851 | $0.6430 | $3.8K |
| Feb 11, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 1,905,115 | $0.6808 | $1.3M |
| Feb 10, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 161,422 | $0.8161 | $131.7K |
| Feb 3, 2026 | Ali Faraz | Chief Executive Officer | A | 158,600 | $0.00 | $0.00 |
| Feb 3, 2026 | Ali Faraz | Chief Executive Officer | A | 952,250 | $0.00 | $0.00 |
| Feb 3, 2026 | Higa Tomohiro | SVP, Finance | A | 29,250 | $0.00 | $0.00 |
| Feb 3, 2026 | Higa Tomohiro | SVP, Finance | A | 175,500 | $0.00 | $0.00 |
| Feb 3, 2026 | Tingley Whittemore | Chief Medical Officer | A | 48,750 | $0.00 | $0.00 |
| Feb 3, 2026 | Tingley Whittemore | Chief Medical Officer | A | 318,500 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.1/10.
MIXED
ANALYST-UPGRADE
1/10
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
1/10
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
May 16, 2026
NEUTRAL
8-K
3/10
Tenaya Therapeutics held its 2026 annual meeting on May 27, 2026, where shareholders approved an ame
May 29, 2026
NEUTRAL
CLUSTER
2/10
Two Tenaya insiders (CMO and SVP Finance) sold a combined $3.7K worth of shares on May 18, 2026, all
May 19, 2026
NEUTRAL
DEFA14A
3/10
Tenaya Therapeutics is holding its annual shareholder meeting to elect three directors, ratify its a
Apr 16, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K indicates a repor
Mar 11, 2026
BULLISH
8-K
8/10
Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to discover
Mar 5, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.00 mean target
+463.4% upside
Strong Buy (1.25)
$2.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7100 |
| Target Low | $2.00 |
| Target Mean | $4.00 |
| Target Median | $3.50 |
| Target High | $8.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.14 | $-0.04 | 54.1% | +39.7% | 1↑ 0↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.10 | $-0.14 | $-0.08 | 17.9% | +16.7% | 4↑ 0↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-0.38 | $-0.59 | $-0.27 | 35.2% | +10.8% | 4↑ 0↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-0.41 | $-0.59 | $-0.29 | -8.2% | +8.4% | 0↑ 1↓ | $0.0B | -100.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.064 | |
| 7d ago | $-0.064 | |
| 30d ago | $-0.107 | +0.042 |
| 60d ago | $-0.107 | +0.042 |
| 90d ago | $-0.130 | +0.066 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
45°
Neutral
Bearish
Neutral
Bullish
6 mentions
0 bullish
1 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 9, 2026
short_volume
Short Volume: TNYA — 56.4% short (1.1M / 1.9M)
Short: 1,079,149 | Exempt: 8,152 | TRF Vol: 1,913,399 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: TNYA — 57.7% short (1.7M / 2.9M)
Short: 1,670,250 | Exempt: 46,408 | TRF Vol: 2,892,794 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TNYA — 61.0% short (1.9M / 3.0M)
Short: 1,851,297 | Exempt: 70,455 | TRF Vol: 3,036,913 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
other
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
<p align="center"><em>All Evaluable Patients Achieved Improvements in Multiple Hallmarks of </em><br><em>MYBPC3-Associated HCM </em></p>
Jun 3, 2026
short_volume
Short Volume: TNYA — 67.2% short (2.2M / 3.3M)
Short: 2,204,200 | Exempt: 26,777 | TRF Vol: 3,278,920 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
routine
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET <pre>Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET</pre>
Jun 1, 2026
short_volume
Short Volume: TNYA — 65.1% short (2.1M / 3.2M)
Short: 2,098,746 | Exempt: 36,166 | TRF Vol: 3,223,774 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
other
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
<p>SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company wi
May 29, 2026
short_volume
Short Volume: TNYA — 59.2% short (1.7M / 3.0M)
Short: 1,749,933 | Exempt: 422 | TRF Vol: 2,954,663 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: TNYA — 58.7% short (1.1M / 1.8M)
Short: 1,078,880 | Exempt: 0 | TRF Vol: 1,838,161 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: TNYA — 63.6% short (0.8M / 1.2M)
Short: 756,211 | Exempt: 92,535 | TRF Vol: 1,189,264 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: TNYA — 59.9% short (2.0M / 3.4M)
Short: 2,046,950 | Exempt: 340,147 | TRF Vol: 3,417,875 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
<p align="center"><em>All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count </em></p>
May 13, 2026
earnings_calendar
TNYA Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
short_volume
Short Volume: TNYA — 56.0% short (4.3M / 7.6M)
Short: 4,283,484 | Exempt: 64,221 | TRF Vol: 7,645,666 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)